رجوع
25
52
نطاق اليوم
KWD 4.46
KWD 4.54
نطاق 52 أسبوعًا
KWD 2.21
KWD 5.34
حجم التداول
800
متوسط 50 يوم / 200 يوم
KWD 4.77
/
KWD 3.81
الإغلاق السابق
KWD 4.49
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Healthcare (626 نظير)
| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | 6.2 | 0.4 |
| P/B | 1.1 | 2.9 |
| ROE % | 18.5 | 3.8 |
| Net Margin % | 2.9 | 3.9 |
| Rev Growth 5Y % | 15.8 | 10.0 |
| D/E | 1.2 | 0.2 |
السعر المستهدف للمحللين
لا تتوفر تغطية محللين
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2029 |
KWD 1.822
KWD 1.743 – KWD 1.898
|
72 B | 1 |
| FY2028 |
KWD 1.545
KWD 1.478 – KWD 1.609
|
64 B | 1 |
| FY2027 |
KWD 1.268
KWD 1.213 – KWD 1.320
|
57 B | 1 |
النقاط الرئيسية
Revenue grew 15.80% annually over 5 years — strong growth
ROE of 18.50% — decent returns on equity
Generating 1.01B in free cash flow
P/E of 6.24 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 4.18%
Capital efficient — spends only 3.17% of revenue on capex
النمو
Revenue Growth (5Y)
15.80%
Revenue (1Y)11.62%
Earnings (1Y)6.15%
FCF Growth (3Y)N/A
الجودة
Return on Equity
18.50%
ROIC12.01%
Net Margin2.93%
Op. Margin5.96%
الأمان
Debt / Equity
1.21
Current Ratio1.46
Interest Coverage2.46
التقييم
P/E Ratio
6.24
P/B Ratio1.08
EV/EBITDA6.29
Dividend Yield0.02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 11.62% | Revenue Growth (3Y) | 13.00% |
| Earnings Growth (1Y) | 6.15% | Earnings Growth (3Y) | 9.78% |
| Revenue Growth (5Y) | 15.80% | Earnings Growth (5Y) | 14.03% |
| Profitability | |||
| Revenue (TTM) | 43.38B | Net Income (TTM) | 1.27B |
| ROE | 18.50% | ROA | 4.99% |
| Gross Margin | 24.75% | Operating Margin | 5.96% |
| Net Margin | 2.93% | Free Cash Flow (TTM) | 1.01B |
| ROIC | 12.01% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 1.21 | Current Ratio | 1.46 |
| Interest Coverage | 2.46 | Dividend Yield | 0.02% |
| Valuation | |||
| P/E Ratio | 6.24 | P/B Ratio | 1.08 |
| P/S Ratio | 0.18 | PEG Ratio | 6.02 |
| EV/EBITDA | 6.29 | Dividend Yield | 0.02% |
| Market Cap | 7.93B | Enterprise Value | 16.25B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 43.38B | 38.86B | 33.97B | 29.07B | 24.13B |
| Net Income | 1.27B | 1.20B | 1.05B | 996.11M | 751.93M |
| EPS (Diluted) | 0.77 | 0.72 | 0.62 | 0.58 | 0.44 |
| Gross Profit | 10.74B | 11.55B | 10.21B | 8.81B | 7.21B |
| Operating Income | 2.59B | 2.37B | 2.08B | 1.48B | 1.22B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 25.46B | 22.14B | 20.09B | 17.19B | 14.78B |
| Total Liabilities | 18.13B | 15.70B | 14.07B | 11.78B | 10.06B |
| Shareholders' Equity | 7.32B | 6.43B | 5.96B | 5.34B | 4.68B |
| Total Debt | 8.83B | 7.70B | 7.07B | 6.06B | 5.18B |
| Cash & Equivalents | 509.36M | 528.00M | 412.32M | 433.54M | 356.12M |
| Current Assets | 14.90B | 12.70B | 11.56B | 9.58B | 7.72B |
| Current Liabilities | 10.19B | 9.22B | 8.08B | 6.37B | 5.90B |
درجات الاستراتيجيات
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
#403 of 616
#121 of 658
النشاط الأخير
دخل
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
دخل
Contrarian Investing (David Dreman)
Mar 24, 2026